CatalystMarker
← board

SRZNW

distress 3/10 · well-funded / low risk
$0.02+9%today-14% from 52w high
surrozen.com44 employeesFounded 2015South San Francisco, CA
Revenue
pre-revenue
Liquidity
$107M
Runway
3.2 yrs
Shares 1y
+36%

Price & events

-14.1% over 6M
$0.01$0.02$0.02Mar 26May 26Jul 262kdilution: 424B5 offering (2026-03-30)dilution: EFFECT shelf_effective (2026-03-30)dilution: S-3 shelf_registration (2026-03-23)
CatalystRating changeDilutionFinancingdashed = today
+9.0%
1D
+0.0%
1W
+0.0%
1M
+0.0%
3M
—
6M
—
1Y
—
2Y
—
5Y
-14.1%
All

Overview

Market Cap
$197.38K
Volume
0
52 Week Range
$0.01 – $0.02
Total Shares
11.61M
Float Shares
5.09M
Beta
0.51

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 11,610,371 · 2 offerings/1y · 0 PIPEs
  • 2026-03-30EFFECTshelf_effective
  • 2026-03-30424B5offering
  • 2026-03-23S-3shelf_registration
  • 2025-08-298-Kmaterial_agreement
  • 2025-08-29424B5offering
  • 2025-05-23EFFECTshelf_effective
  • 2025-05-20S-3shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.